HomeStock SectorsBioTechMedical Groups Sue RFK...

Medical Groups Sue RFK Jr. For Assault On Science Over Unlawful COVID-19 Vaccine Rollbacks – Novavax (NASDAQ:NVAX), Moderna (NASDAQ:MRNA)

In a significant legal challenge that could reshape the future of public health policy in the United States, a powerful alliance of leading medical and public health organizations, including the American Academy of Pediatrics (AAP), the American College of Physicians (ACP), and the American Public Health Association (APHA), filed a lawsuit on Monday against Secretary of Health and Human Services Robert F. Kennedy Jr.

The plaintiffs contend that Secretary Kennedy has launched an “assault on science, public health, and evidence-based medicine” through unilateral and arbitrary changes to COVID-19 vaccine recommendations for children and pregnant individuals.

This unprecedented legal action seeks to halt what the coalition describes as an “existential threat to vaccination in America,” arguing that Kennedy’s directives, including the controversial dismissal of expert advisors from the CDC’s immunization committee, are endangering the nation’s long-standing, science-based vaccine infrastructure and, critically, the health of its most vulnerable populations.

Also Read: Lawmakers Investigate Whether Pfizer Delayed COVID-19 Vaccine Results For Political Reasons

Lawsuit Details And Allegations

The comprehensive lawsuit, filed in the U.S. District Court for the District of Massachusetts, names the U.S. Department of Health and Human Services (HHS) and Secretary Robert F. Kennedy Jr. as defendants. The plaintiffs, which also include the Infectious Diseases Society of America (IDSA), the Massachusetts Public Health Alliance (MPHA), the Society for Maternal-Fetal Medicine (SMFM), and a pregnant physician, assert that Kennedy acted “arbitrarily and capriciously” by altering COVID-19 vaccine recommendations for children and pregnant people without scientific basis.

This follows Secretary Kennedy’s public statement in May, where he expressed pleasure at the removal of the COVID-19 vaccine for healthy children and pregnant women from CDC recommended immunization schedules.

A critical aspect of the lawsuit’s complaint is Secretary Kennedy’s alleged unjust dismissal of 17 members of the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP). These experts were reportedly replaced with individuals known for espousing anti-vaccine viewpoints.

Dr. Susan J. Kressly, President of the AAP, underscored the gravity of these actions, stating, “This wasn’t just sidelining science. It’s an attack on the very foundation of how we protect families and children’s health. And the consequences could be dangerous.”

The lawsuit further details a pattern of interference, including blocked CDC communications, delayed or canceled meetings of CDC and Food and Drug Administration (FDA) vaccine advisers, and the announcement of studies to investigate non-existent links between vaccines and autism.

Seeking Injunctions And Protecting Public Health

The plaintiffs are seeking both preliminary and permanent injunctions to reverse Secretary Kennedy’s rescissions of COVID-19 vaccine recommendations. They also request a declaratory judgment to legally pronounce these changes as unlawful. Richard H. Hughes IV, lead counsel for the plaintiffs and partner at Epstein Becker Green, voiced grave concerns, asserting, “This administration is an existential threat to vaccination in America, and those in charge are only just getting started. If left unchecked, Secretary Kennedy will accomplish his goal of ridding the United States of vaccines, which would unleash a wave of preventable harm on our nation’s children.”

The lawsuit alleges that the Directive is but one example of the Secretary’s agenda to dismantle the long-standing, Congressionally-authorized, science- and evidence-based vaccine infrastructure that has prevented the deaths of untold millions of Americans. The filing highlights that the Secretary’s dismantling of the vaccine infrastructure must end, and halting this effort begins with vacating the Directive.

FDA’s Internal Disagreements And Historical Legal Actions

Per a recent media report, Dr. Vinay Prasad, the U.S. Food and Drug Administration’s (FDA) top vaccine official, overruled agency scientists to limit approval of two COVID-19 vaccines, despite internal recommendations to clear them for broader use.

FDA scientists had recommended full approval for updated COVID vaccines from Novavax Inc. NVAX and Moderna Inc. MRNA for individuals aged 12 and older, citing favorable risk-benefit analyses.

But Prasad restricted the shots to those at higher risk, seniors and people with underlying health conditions, arguing that declining hospitalization and death rates from COVID-19 shifted the balance of risks and benefits.

While distinct from the HHS lawsuit, this report underscores a broader climate of scrutiny and debate surrounding vaccine policy.

The AAP has a history of pursuing legal action against the federal government, regardless of political affiliation. Past instances include a 1983 lawsuit against HHS regarding life-sustaining treatment for infants and separate lawsuits against the FDA in 2016 and 2018 concerning graphic warnings on cigarettes and e-cigarette regulation, respectively.

Price Action: MRNA stock is trading higher by 11% to $33.18, and NVAX stock is up 6.61% at $7.05 at last check Tuesday.

Read Next:

Photo by lev radin via Shutterstock

Most Popular

More from Author

Illiquid, Overvalued Assets Spark Market Fears as Buyers Retreat

As "dip buyers" get eviscerated, more dominos fall, and at a...

Why Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday? – ZyVersa Therapeutics (NASDAQ:ZVSA)

ZyVersa Therapeutics, Inc. ZVSA stock was trading higher on Tuesday, with a...

US Dollar Gains as Tariff Letters Erode Risk Appetite

Trump letters and August 1 deadline in focus Dollar strengthens as both...

Read Now

Calidi Biotherapeutics Stock Jumps 39% After Hours — What’s Going On – Calidi Biotherapeutics (AMEX:CLDI), Mustang Bio (NASDAQ:MBIO)

Calidi Biotherapeutics Inc. CLDI stock surged by 39.47% in the after-hours trading session on Tuesday. The stock price increased by $0.095, reaching $0.34. The company’s stock had closed at $0.24 on the same day.What Happened: The stock’s after-hours surge comes on the heels of a development in...

Illiquid, Overvalued Assets Spark Market Fears as Buyers Retreat

As "dip buyers" get eviscerated, more dominos fall, and at a tipping point, the herd realizes the tide has reversed and it’s time to sell--but alas, it’s too late. Illiquid, Overvalued describes a great many assets that are on the books as "rock-solid investments." Illiquidity...

Why Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday? – ZyVersa Therapeutics (NASDAQ:ZVSA)

ZyVersa Therapeutics, Inc. ZVSA stock was trading higher on Tuesday, with a session volume of 160.9 million compared to the average volume of 4.03 million as per data from Benzinga Pro.What HappenedZyVersa Therapeutics provided regulatory and product support for FDA-authorized Emergency Compassionate Use of Cholesterol Efflux Mediator VAR 200...

US Dollar Gains as Tariff Letters Erode Risk Appetite

Trump letters and August 1 deadline in focus Dollar strengthens as both China and the EU avoid tariff letters Equities are wobbly, while gold confirms lingering demand Aussie gains as RBA surprises by keeping rates unchanged Liberation Date: Version 2The approval of the US Budget Bill has allowed US President Trump...

Wall Street Is On Fire—So Why Is This Wall Of Cash Moving Abroad? – iShares Core MSCI Emerging Markets ETF (ARCA:IEMG)

U.S. stocks may be breaking records, but a flood of investor cash is moving elsewhere—toward emerging markets, where valuations are cheaper, currencies are strengthening and years of underperformance may finally be reversing.The iShares Core MSCI Emerging Markets ETF IEMG has attracted $7.4 billion in inflows so far...

Why CARGO Therapeutics Stock Is Gaining Today – Cargo Therapeutics (NASDAQ:CRGX)

CARGO Therapeutics Inc. CRGX saw its stock climb on Tuesday after the biotech firm announced a merger agreement with Concentra Biosciences LLC.Under the terms of the agreement, Concentra will acquire CARGO for $4.379 in cash per share, along with a non-transferable contingent value right.The CVR entitles shareholders...

Gold Prices Slip Amid Trump’s Tariff Delay and Fed Rate Cut Speculations

Gold Pressured by Trade Tariffs On Monday, U.S. President Donald Trump posted letters on Truth Social addressed to the leaders of 14 countries. He threatened to impose tariffs ranging from 25% to 40% on imports unless countries address trade imbalances. The letters targeted China, Germany, Japan, Mexico, and...

Artelo Biosciences Analyst See It As An Emerging Biotech – Artelo Biosciences (NASDAQ:ARTL)

D. Boral Capital upgraded Artelo Biosciences, Inc. ARTL on Tuesday.The analyst upgraded from Hold to Buy and introduced a price forecast of $20.Analyst Jason Kolbert wrote, “We continue to view Artelo as an emerging biotechnology company focused on Cachexia and chemotherapy-induced peripheral neuropathy (CIN) with the lead...

Oil Prices Rebound Despite OPEC+ Output Hike as Markets Rethink Supply Risk

surged yesterday after gapping down over the weekend. The gap down came about as the + group, which includes OPEC and its allies, agreed to increase oil production by 548,000 barrels per day in August. This is a bigger rise compared to the 411,000 barrels per day...

Asian Stocks Climb as Trump Signals Openness to Trade Talks Before Tariff Deadline

Asian stock markets remained steady despite the latest update on US President Donald Trump’s tariff plans. On Tuesday, the stayed strong, and dropped. In the US, stock prices fell after Trump sent letters to 14 countries, including Japan and South Korea, announcing much higher tariffs on...

Why Is Cogent Biosciences Stock Soaring On Tuesday? – Cogent Biosciences (NASDAQ:COGT)

On Monday, Cogent Biosciences, Inc. COGT said bezuclastinib showed meaningful clinical benefit for patients with non-advanced systemic mastocytosis.The company said that its experimental drug reduced the symptoms of a chronic immune disorder called non-advanced systemic mastocytosis.The latest study demonstrated meaningful and highly statistically significant improvements across the...

Are Markets Underpricing the Next Tariff Shock?

Economic activity appears set to strengthen in the official Q2 , but the second half of the year looks relatively vulnerable. One factor is the possibility that the simmering trade war may heat up after President Trump on Monday announced new tariffs set to begin on August...